Previous Statements by MRK
» Merck & Co.'s CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Merck & Co. Inc. - Special Call
» Merck & Co.'s CEO Discusses Q3 2011 Results - Earnings Call Transcript
Next, we've also provided tables to help you understand the revenue trends, so there are tables with the GAAP results, and then there are also tables that -- Table 2, which reconciles GAAP P&L to non-GAAP, and Table 3 provides the sales performance of the company, business and the units. During the call, we're going to primarily refer to Table 2 and Table 3 when we talk about performance.Finally, I'd like to remind you that some of the statements we make during today's call might be considered forward-looking statements. And as such, such statements are based upon the current beliefs of management and are subject to significant risks and uncertainties. The company's SEC filings, including our 10-K, which was filed for 2011 back at the end of February identifies certain risk factors and cautionary statements that could cause the company's actual results to differ materially from any projected this morning. Merck undertakes no obligation to publicly update any forward-looking statement and you can find our SEC filings, as well as today's earnings release and tables on our website at merck.com. This morning, I'm joined by Ken Frazier, our President and Chief Executive Officer and Chairman of the Board; Adam Schechter, our President of Global Human Health; and Peter Kellogg, our Chief Financial Officer. Now I'd like to introduce Ken Frazier. Kenneth C. Frazier Thank you, Alex. Good morning, everyone, and thank you all for joining the call today. Our performance in the first quarter underscores key things that we've emphasized since early 2011: growth and execution. We remain committed to building shareholder value through continued execution while focusing on both performance and innovation. All in all, this quarter showed a strong start in a year when we intend to overcome a significant patent expiry. We are building momentum, particularly with our key growth drivers and plan to achieve numerous major milestones in our late stage pipeline, including a series of important filings with significant commercial potential. Our focus on aligned execution across geographies and divisions allowed us to deliver worldwide sales of $11.7 billion in the quarter, with solid growth in each of our 3 major businesses, 6% in the global pharmaceutical and vaccines business when one excludes the impact of the J&J arbitration, 7% in Consumer Care and 8% in Animal Health. It should be noted that we delivered this growth while also tightly managing costs, resulting in an 8% growth in non-GAAP EPS. Once again, we saw double-digit growth from a number of key products in our global pharmaceutical and Vaccines business. As always, Adam Schechter will discuss the performance of our product portfolio in more detail.
Consumer Care growth was due to strong performance from brands across the consumer product portfolio in both developed and developing markets, including the U.S., Canada, Russia and Brazil. Animal Health growth was driven by the top 20 products in the portfolio, which grew a combined 18%, excluding foreign exchange, in the quarter. Overall, I remain pleased with the long-term global trends and the growth prospects for both the Consumer Care and Animal Health businesses.As you know, this is a challenging period for many companies in the industry due to major patent expirations, continued uncertainty in the global economy and increasing external pressures in the macro health care environment. However, we are confident in our ability to successfully manage these pressures and improve Merck's competitive position over the long term. In fact, we believe the growth momentum of our underlying business and the strength of our late stage pipeline position us well as we prepare for the SINGULAIR patent expiry and beyond. In 2012, we intend to maintain our revenues at or near 2011 level on a constant currency basis and drive bottom line growth. In addition to executing our core business strategies, we also made progress in our efforts to expand in the emerging markets. For the quarter, emerging market sales represented 17% of total pharmaceutical sales. China alone grew 19%, including a 5% benefit from foreign exchange. We continue to estimate that the emerging markets will represent about 1/4 of our total pharmaceutical and vaccine sales by the end of 2013. Read the rest of this transcript for free on seekingalpha.com